{"config":{"lang":["en"],"separator":"[\\s\\-]+","pipeline":["stopWordFilter"]},"docs":[{"location":"","title":"ALS TDI RWE Resources","text":""},{"location":"#table-of-contents","title":"Table of Contents","text":"<ul> <li>Introduction</li> <li>ALS TDI OMOP Data Set</li> <li>OMOP/OHDSI Resources</li> <li>Free RWE Resources</li> <li>Authors</li> </ul>"},{"location":"als-tdi-omop-data-set/","title":"\ud83d\udce6 Release Notes: Version 0.1.0","text":"<p>The first release of the ALS TDI ARC Study, mapped to the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM), restructures a subset of the ARC Natural HIstory Study into the OMOP CDM structure and maps a subset to standardized vocabularies.</p> <p>This is part of a larger harmonization effort with Answer ALS and the Critical Path Institute.</p>"},{"location":"als-tdi-omop-data-set/#complete-data-set-and-documentation-location","title":"\ud83d\udcc1 Complete Data Set and Documentation Location","text":"<p>Neuromine Data Portal</p>"},{"location":"als-tdi-omop-data-set/#cdm-version","title":"\ud83e\uddee CDM Version","text":"<ul> <li>OMOP CDM Version 5.4 \u2013 View Documentation</li> </ul>"},{"location":"als-tdi-omop-data-set/#participant-summary","title":"\ud83d\udc65 Participant Summary","text":"<ul> <li>Total number of participants: 1,676   <p>Note: not all participants answered all surveys</p> </li> </ul> <p>The dataset contains data from the following participant types: - People with ALS - Asymptomatic carriers - Healthy controls  </p> <p>Participant type can be found in the Person table, under the participant_source column.</p> <p>This version of the ALS TDI dataset includes: - Self-reported surveys and ALSFRS-R (ALS Functional Rating Scale \u2013 Revised) data - Laboratory results from analyzed blood samples</p>"},{"location":"als-tdi-omop-data-set/#citation","title":"\ud83d\udcda Citation","text":"<p>ALS Therapy Development Institute (ALS TDI). (2023). ALS Research Collaborative (ARC) [Data set].  Amyotrophic Lateral Sclerosis Therapy Development Institute.   https://doi.org/10.71944/C3NA-9124</p>"},{"location":"als-tdi-omop-data-set/#mappings","title":"\ud83e\udde9 Mappings","text":"<ul> <li> <p>\ud83e\uddcd Person:   Demographics including year of birth, sex, race, and ethnicity.   See accepted concepts here.</p> </li> <li> <p>\ud83d\uddd2\ufe0f Observation:  </p> </li> <li>ALSFRS-R (individual items and total score)  </li> <li>Family and personal medical history  </li> <li>Site of onset  </li> <li>Injury history  </li> <li>Military service  </li> <li> <p>Tobacco use</p> </li> <li> <p>\ud83d\udc8a Drug Exposure:   Medications and select supplements</p> </li> <li> <p>\u26b0\ufe0f Mortality:   Date of death</p> </li> <li> <p>\ud83e\uddea Measurement:  </p> </li> <li>Laboratory data from blood draws  </li> <li> <p>Self-reported genetic mutations</p> </li> <li> <p>\ud83d\udccc Other Variables:  </p> </li> <li>Military service  </li> <li>Industry of employment  </li> <li>Injury history</li> </ul>"},{"location":"als-tdi-omop-data-set/#notes-on-mapping-decisions","title":"\ud83d\udccc Notes on Mapping Decisions","text":""},{"location":"als-tdi-omop-data-set/#dates-and-timing","title":"\ud83d\uddd3\ufe0f Dates and Timing","text":"<p>Dates may be shifted for deidentification purposes using the method described in:</p> <p>Hripcsak G, Mirhaji P, Low AF, Malin BA.  Preserving temporal relations in clinical data while maintaining privacy.  J Am Med Inform Assoc. 2016 Nov;23(6):1040-1045. Link to publication </p> <p>In the Observation Period OMOP domain: - observation_period_start_date = first event date (usually first survey) - observation_period_end_date = last event date or date of death</p>"},{"location":"als-tdi-omop-data-set/#missing-data","title":"\u2753 Missing Data","text":"<p>If a data point was not collected, it is excluded unless required by OMOP CDM. See the \"Required\" column in the CDM v5.4 guidance</p> <p>Examples: - If ethnicity is unknown \u2192 concept_id = 0 - If race is unknown or multiple \u2192 concept_id = 0</p>"},{"location":"als-tdi-omop-data-set/#custom-concepts","title":"\ud83d\udee0\ufe0f Custom Concepts","text":"<p>What are custom concepts? In the OMOP Common Data Model, most clinical information is standardized using concept IDs from shared vocabularies (like SNOMED, RxNorm, LOINC, etc.). However, sometimes source data includes important information that doesn\u2019t have an existing standardized concept in these vocabularies.</p> <p>In those cases, researchers define custom (or local) concepts with unique concept IDs (usually starting above 2,000,000,000). These custom concepts allow valuable variables \u2014 such as ALS symptom onset patterns, survey-specific fields, or patient-reported values \u2014 to be included in the dataset in a structured, queryable way.</p> <p>In the ALS TDI OMOP data set, custom concepts were created for: - ALS symptom onset - Anatomical site of symptom onset - Additional variables unique to the ARC study</p> <p>These custom concepts are stored and referenced just like standard concepts, allowing them to be queried and analyzed using the same OMOP framework.</p>"},{"location":"als-tdi-omop-data-set/#medications","title":"\ud83d\udc8a Medications","text":"<ul> <li>Mapped to ingredient level wherever possible  </li> <li>Dose not calculated </li> <li>All source values retained </li> <li>If the drug or supplement was unmapped:</li> <li>concept_id = 0</li> <li>Source data included in the appropriate source column</li> </ul>"},{"location":"als-tdi-omop-data-set/#guidance-for-using-this-data-set","title":"\ud83e\udded Guidance for Using This Data Set","text":"<ul> <li> <p>\ud83d\udd0d Review the _source_value or _source_concept_id columns in each OMOP table to understand how data were originally captured. These often contain verbatim responses or terms from the source survey.</p> </li> <li> <p>\ud83e\udde0 Explore concept definitions and standardized codes using the OHDSI Athena tool. You can look up concept IDs used throughout the dataset and understand their relationships and domains.</p> </li> </ul>"},{"location":"authors/","title":"Authors","text":"<p>This guide was developed by:</p> <ul> <li>Danielle Boyce, MPH, DPA, Principal Investigator, Real World Evidence  </li> <li>Hannah Walters, MPH, PhD, Postdoctoral Researcher  </li> <li>Alan Premasiri, MS, Director of Clinical Operations  </li> <li>Fernando Vieira, MD, Chief Executive Officer/Chief Scientific Officer  </li> </ul> <p>ALS Therapy Development Institute Contact: dboyce@als.net</p>"},{"location":"free-rwe-resources/","title":"Free RWE Resources","text":"<p>These curated, freely accessible resources provide foundational knowledge, practical examples, and step-by-step instructions for navigating Real World Evidence (RWE), OHDSI, OMOP, and related frameworks:</p> <ul> <li> <p>Book: Guide to Real-World Data for Clinical Research   By Danielle Boyce (ALS TDI) and Pavel Goriacko (Montefiore) Visit rwd.guide</p> </li> <li> <p>Online Course: Introduction to OMOP: Your Frequently Asked Questions Answered   Taught by Danielle Boyce (ALS TDI) and Pavel Goriacko (Montefiore) Enroll in the course</p> </li> <li> <p>Curated Resource Overview: OHDSI, OMOP, and FHIR for Neurodegenerative Disease Researchers   Created by Danielle Boyce (ALS TDI) Access the resource</p> </li> </ul>"},{"location":"introduction/","title":"Introduction","text":"<p>Real World Evidence (RWE) plays a critical role in understanding disease progression, evaluating treatment outcomes, and supporting clinical decision-making. Unlike controlled clinical trials, RWE leverages observational data from diverse real-world settings. This book provides foundational resources, practical guidance, and comprehensive documentation for researchers, clinicians, and data scientists interested in RWE methodologies, with a special focus on ALS research using the OMOP Common Data Model (CDM).</p>"},{"location":"omop-ohdsi-resources/","title":"OMOP/OHDSI Resources","text":"<p>This chapter contains practical resources for working with Observational Health Data Science and Informatics (OHDSI) community resources and Observational Medical Outcomes Partnership (OMOP) data, including an interactive OMOP data dictionary, code snippets for common analytic tasks using a variety of software, and examples of observational research projects suited to OMOP/OHDSI frameworks.  For a good overview of OHDSI/OMOP, please see the resources in the chapter, \"Free RWE Resources.\"</p> <p>Resources include:</p> <ul> <li>Interactive OMOP CDM Data Dictionary</li> <li>Analytic Use Cases and Research Examples</li> <li>OMOP Code Snippets (SQL, R, Python)</li> </ul>"},{"location":"omop-ohdsi-resources/#omop-cdm-basic-data-dictionary","title":"\ud83d\udcca OMOP CDM Basic Data Dictionary","text":"<p>For a sample interactive OMOP data dictionary detailing the fields in the OMOP CDM, please click on the thumbnail below. For the specific ARC study data dictionary, visit the Neuromine Data Portal.</p> <p></p>"},{"location":"omop-ohdsi-resources/#projects-best-suited-for-observational-research-and-ohdsi-network-studies","title":"\ud83d\udcc8 Projects Best Suited for Observational Research and OHDSI Network Studies","text":"\ud83e\uddea Analytic Use Cases and Examples Analytic Use Case Type Structure Example Clinical Characterization Disease Natural History Amongst patients who are diagnosed with &lt;insert your disease of interest&gt;, what are the patient\u2019s characteristics from their medical history? Amongst patients with rheumatoid arthritis, what are their demographics (age, gender), prior conditions, medications, and health service utilization behaviors? Treatment Utilization Amongst patients who have &lt;insert your disease of interest&gt;, which treatments were patients exposed to amongst &lt;list of treatments for disease&gt; and in which sequence? Amongst patients with depression, which treatments were patients exposed to SSRI, SNRI, TCA, bupropion, esketamine and in which sequence? Outcome Incidence Amongst patients who are new users of &lt;insert your drug of interest&gt;, how many patients experienced &lt;insert your known adverse event of interest from the drug profile&gt; within &lt;time horizon following exposure start&gt;? Amongst patients who are new users of methylphenidate, how many patients experienced psychosis within 1 year of initiating treatment? Population-level Effect Estimation Safety Surveillance Does exposure to &lt;insert your drug of interest&gt; increase the risk of experiencing &lt;insert an adverse event&gt; within &lt;time horizon following exposure start&gt;? Does exposure to ACE inhibitor increase the risk of experiencing Angioedema within 1 month after exposure start? Comparative Effectiveness Does exposure to &lt;insert your drug of interest&gt; have a different risk of experiencing &lt;insert any outcome (safety or benefit)&gt; within &lt;time horizon following exposure start&gt;, relative to &lt;insert your comparator treatment&gt;? Does exposure to ACE inhibitor have a different risk of experiencing acute myocardial infarction while on treatment, relative to thiazide diuretic? Patient-level Prediction Disease Onset and Progression For a given patient who is diagnosed with &lt;insert your disease of interest&gt;, what is the probability that they will go on to have &lt;another disease or related complication&gt; within &lt;time horizon from diagnosis&gt;? For a given patient who is newly diagnosed with atrial fibrillation, what is the probability that they will go on to have ischemic stroke in next 3 years? Treatment Response For a given patient who is a new user of &lt;insert your chronically-used drug of interest&gt;, what is the probability that they will &lt;insert desired effect&gt; in &lt;time window&gt;? For a given patient with T2DM who starts on metformin, what is the probability that they will maintain HbA1C &lt;6.5% after 3 years? Treatment Safety For a given patient who is a new user of &lt;insert your drug of interest&gt;, what is the probability that they will experience &lt;insert adverse event&gt; within &lt;time horizon following exposure&gt;? For a given patient who is a new user of warfarin, what is the probability that they will have GI bleed in 1 year?"},{"location":"omop-ohdsi-resources/#source-ohdsi-2023-save-our-sisyphus-challenge-slides-pdf","title":"Source: OHDSI. (2023). Save Our Sisyphus Challenge Slides (PDF)","text":""},{"location":"omop-ohdsi-resources/#omop-code-snippets","title":"\ud83d\udcbb OMOP Code Snippets","text":"<p>We provide a publicly available set of OMOP code snippets used in the I-LEARN Course to help learners explore and analyze OMOP Common Data Model datasets using tools like R, SQL, and Python.</p> <p>\ud83d\udd17 Repository: BoyceLab/OMOP-Code-Snippets-for-I-LEARN-Course</p>"},{"location":"omop-ohdsi-resources/#what-youll-find-in-this-repository","title":"\ud83e\uddf0 What You'll Find in this Repository","text":"<p>The repository contains example scripts and templates to:</p> <ul> <li>Query OMOP data using SQL</li> <li>Analyze OMOP-mapped data using R</li> <li>Connect and run queries via RPostgreSQL</li> <li>Explore how standard concepts relate to source codes</li> </ul>"},{"location":"omop-ohdsi-resources/#folder-highlights","title":"\ud83d\udcc2 Folder Highlights","text":"<ul> <li>SQL/: Ready-to-use SQL queries for common OMOP domains (e.g., drug exposure, observation).</li> <li>R/: R scripts that demonstrate how to load, analyze, and visualize OMOP data.</li> <li>concepts/: Examples for working with concept_id and concept_relationship tables.</li> </ul>"},{"location":"omop-ohdsi-resources/#use-cases","title":"\ud83d\udcd8 Use Cases","text":"<p>These snippets are designed for: - Learners in the Tufts CTSI I-LEARN course - Researchers new to OHDSI/OMOP - Analysts working with OMOP-formatted ALS datasets</p>"}]}